CoreCap Advisors
XENE icon

CoreCap Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

CoreCap Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$632 Sell
17
-13
-43% -$772 ﹤0.01% 2755
2026
Q2 		$1.81K Buy
30
+13
+76% +$722 ﹤0.01% 2561
2026
Q1 		$989 Hold
17
– – ﹤0.01% 2535
2025
Q4 		$762 Buy
+17
New +$714 ﹤0.01% 2643

Other funds holding XENE

KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Elmwood Wealth Management
Elmwood Wealth Management Berkeley, California $416M AUM 11.87% 1-Year Est. Return
Wedmont Private Capital
Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Harbor Investment Advisory
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return

CoreCap Advisors's XENE Position: Q3 2026 in Review

CoreCap Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 43% in Q3 2026, selling an estimated $772 and leaving 17 shares worth $632. The position accounts for ﹤0.01% of the portfolio, ranked #2755.

CoreCap Advisors first reported a position in XENE in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.81K in Q2 2026. 21 funds tracked by Wall St. Rank hold XENE as of Q3 2026.

  • CoreCap Advisors held 17 shares of Xenon Pharmaceuticals worth $632 as of Q3 2026.
  • CoreCap Advisors sold 13 Xenon Pharmaceuticals shares in Q3 2026, an estimated $772.
  • Xenon Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2755 holding.
  • CoreCap Advisors first reported a position in Xenon Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • CoreCap Advisors's Xenon Pharmaceuticals position peaked at $1.81K in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.